[go: up one dir, main page]

MX2024011674A - Agonistas del receptor a1a-adrenérgico y métodos de uso. - Google Patents

Agonistas del receptor a1a-adrenérgico y métodos de uso.

Info

Publication number
MX2024011674A
MX2024011674A MX2024011674A MX2024011674A MX2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A MX 2024011674 A MX2024011674 A MX 2024011674A
Authority
MX
Mexico
Prior art keywords
adrenergic receptor
methods
alpha
receptor agonists
prodrug
Prior art date
Application number
MX2024011674A
Other languages
English (en)
Inventor
Wei Chen
Counde O'yang
Anthony P Ford
David Scott Carter
Original Assignee
Curasen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curasen Therapeutics Inc filed Critical Curasen Therapeutics Inc
Publication of MX2024011674A publication Critical patent/MX2024011674A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción se basa, al menos en parte, en la identificación de compuestos que modulan el receptor adrenérgico y métodos de uso de los mismos para tratar enfermedades asociadas con un receptor adrenérgico. Por ejemplo, en la presente se describe un compuesto de acuerdo con la Fórmula (I) o un estereoisómero ópticamente puro, una sal farmacéuticamente aceptable, un solvato o un profármaco del mismo.
MX2024011674A 2022-03-24 2023-03-22 Agonistas del receptor a1a-adrenérgico y métodos de uso. MX2024011674A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323421P 2022-03-24 2022-03-24
PCT/US2023/015914 WO2023183394A1 (en) 2022-03-24 2023-03-22 Alpha 1a-adrenergic receptor agonists and methods of use

Publications (1)

Publication Number Publication Date
MX2024011674A true MX2024011674A (es) 2024-09-27

Family

ID=88101941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011674A MX2024011674A (es) 2022-03-24 2023-03-22 Agonistas del receptor a1a-adrenérgico y métodos de uso.

Country Status (7)

Country Link
EP (1) EP4499070A1 (es)
KR (1) KR20240165433A (es)
CN (1) CN119013020A (es)
AU (1) AU2023240170A1 (es)
IL (1) IL315798A (es)
MX (1) MX2024011674A (es)
WO (1) WO2023183394A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2337909C2 (ru) * 2002-02-01 2008-11-10 Ф.Хоффманн-Ля Рош Аг Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
CN101374516A (zh) * 2006-01-27 2009-02-25 弗·哈夫曼-拉罗切有限公司 取代的咪唑啉的2-咪唑衍生物的用途
EP3421471B1 (en) * 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds

Also Published As

Publication number Publication date
IL315798A (en) 2024-11-01
CN119013020A (zh) 2024-11-22
EP4499070A1 (en) 2025-02-05
KR20240165433A (ko) 2024-11-22
AU2023240170A1 (en) 2024-10-31
WO2023183394A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
CL2024001025A1 (es) Compuestos como agonistas de glp-1r
CR20220371A (es) Agonistas heterocíclicos de glp-1
MX2023001311A (es) Agonistas heterociclicos de glp-1.
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
MX2022006986A (es) Inhibidores de kras g12c.
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
PH12021552805A1 (en) Cdk inhibitors
MX2023010411A (es) Inhibidores de erbb/btk.
CO5150232A1 (es) METODO Y COMBINACION QUE UTILIZAN (+) NORCISAPRIDA EN COMBINACION CON INHIBIDORES DE BOMBA DE PROTONES O ANTAGONISTAS DEL RECEPTOR H[sub 2]
MX2024000230A (es) Inhibidores de cdk2.
MX2023001671A (es) Procedimiento y compuesto para su uso en el tratamiento y/o prevención de la netosis.
ECSP22092977A (es) Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
MX2022008626A (es) Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
MX2019009954A (es) Metodos para el tratamiento de pacientes con neoplasias malignas hematologicas.
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
CO2024002909A2 (es) Derivado de triazol sustituido, método de preparación del mismo, composición farmacéutica del mismo y uso del mismo
MX2024011674A (es) Agonistas del receptor a1a-adrenérgico y métodos de uso.
MX2022013843A (es) Inhibidores de il4i1 y metodos de uso.
MX2023005821A (es) Agonista beta adrenergico y metodos de uso del mismo.
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
BR112023015721A2 (pt) Derivados tricíclicos úteis como inibidores de parp7
MX2023002276A (es) Agonistas del receptor adrenérgico a1a y métodos de uso.
CR20240014A (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
MX2023003631A (es) Indazoles a manera de inhibidores de cinasa 1 progenitora hematopoyetica (hpk1) y metodos de uso de los mismos.
CR20200636A (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria